Cytorex Biosciences, Inc. Corporate Presentation 2013

Introduction This presentation describes an investment opportunity in Cytorex Bioscience, Inc.; a Florida based preclinical stage Biopharmaceutical Company developing new therapies based on its expertise in pharmacologically active low pH acidic formulations. Cytoreg ®, the Company’s lead drug candidate, is currently in preclinical development for various cancers.

Market Overview In 2007, worldwide sales of cancer therapies totaled USD $42.2 billion. Within the 7 major markets (US, Japan, France, Germany, Italy, Spain, and the United Kingdom), sales amounted to USD $34.3 billion. These sales are expected to grow at a compound annual growth rate (CAGR) of 12% between 2006 and 2013, almost 3 times faster than the pharmaceutical industry as a whole, reaching USD $55 billion by 2012.

Focus Cytorex intends to initially focus development efforts of Cytoreg ® on cancer types with high levels of unmet need: Glioblastoma Multiforme (grade IV brain tumor); pancreatic cancer; and metastatic melanoma. Cytoreg ® may also be developed for brain metastases. These four cancer types have low survival rates, are currently underserved with existing marketed therapies and have few pipeline products.

Technology Overview Cytorex has developed a number of therapeutic candidates based on its US patented pharmacologically active low pH acidic technology for a wide range of disorders, including cancer and diseases of immunological origin. Cytoreg® is Cytorex lead drug candidate and is the primary focus of this presentation. Cytoreg®, a novel cancer therapeutic candidate, is a formulation of balanced acids, where hydrofluoric acid (HF) is the key active ingredient. Cytoreg® may be used to treat several types of cancers, including solid tumors and hematological malignancies.

Portfolio PRODUCTSTAGEAPPLICATION 1 Cytoreg™: Developmen t Currently in preclinical development stage for these indications: 1) Brain Tumors (Glioblastoma Multiforme); 2) Pancreatic Cancer and 3) Metastatic Melanoma (skin cancer). Also being investigated in brain metastases. 2 CytoregUNO™ Developmen t skin cancer such as basal cell cancer, squamous cell cancer, sarcoma, melanoma, and disorders caused by fungi, viruses and bacteria on the skin. 3 CytoCardio™DiscoveryProduct for treatment of hypertension 4 CytoKStones ™:DiscoveryProduct for treatment of Kidney Stones 5 CytoNeuroSys™Discovery Product for treatment of MS, Alzheimer’s, Parkinson’s, and chronic diseases like epilepsy. 6 CytoOS™DiscoveryProduct for treatment of Otosclerosis 7 CytoDiabet™Discovery Product for treatment/regulation of Diabetes 8 CytoAntioxidant ™ DiscoveryAntioxidant 9 CytoHormone™Discovery Product for treatment of hormonal disorders 10 CytoACV™Discovery Product for treatment of Ischemic Shock. 11 CytoSepsis™DiscoveryProduct for treatment of sepsis.

Selectivity and MOA Preclinical studies in Glioblastoma Multiforme and other cancer cell types have demonstrated that Cytoreg ® has high specificity and selectivity in targeting and inhibiting cancer growth, as well as inducing selective apoptosis. Mechanisms of action studies have also been performed to understand how Cytoreg ® kills cancer cells. These studies have demonstrated that Cytoreg ® : disrupts the cell membrane in brain cancer cell lines; acts independently of the tumor suppressor gene p53 and caspase cascade pathways; inhibits cancer cell growth factor; and induces selective apoptosis.

Key product advantages A targeted therapy with multiple mechanisms of action. Demonstrated potential to reduce tumor mass and/or stops tumor growth or even destroys the tumor. Favorable side effect profile, as demonstrated in human compassionate use program and in preclinical studies performed to date. Very low manufacturing costs.

Clinical Development Plan & Regulatory Strategy The Company expects that Cytoreg® will be brought to market at a much faster pace than typical oncology products by targeting indications with high levels of unmet need, including Glioblastoma Multiforme; pancreatic cancer; and metastatic melanoma. By focusing on these indications, Cytoreg® will be a candidate for Fast Track and Orphan Drug designations, and potentially accelerated approval by US Food & Drug Administration (USFDA). Our initial plan is to perform some preliminary clinical trials in Latin America, get approval for at least two indications, and then start the FDA/EMA approval process. If Funding is sufficient we may choose to initiate Clinical Trials directly in the USA.

Intellectual Property Cytorex believes the Company’s intellectual property (IP) position is secure. The Company has one issued patent (US patent 7,141,251, “Pharmacologically Active Strong Acid Solutions”) containing over 70 claims related to composition and therapeutic use. Cytorex has developed a detailed patent prosecution strategy to further enhance its IP position in the US and worldwide. Cytorex’ IP estate has been reviewed by Mr. Michael Keller, Esq. Mr. Keller has over 20 years’ experience prosecuting biomedical drug, diagnostic and device patents.

Key Milestones (I) Continue to prosecute and develop Cytoreg®’s intellectual property portfolio. Complete Series A financing in 2013 Meet with a Latin America country Regulator (Mexico, Argentina or Brazil) for pre- Investigational New Drug (IND) meeting in early Q

Key Milestones (II) Meet with USFDA for pre-Investigational New Drug (IND) meeting in early Q Receive IND clearance from USFDA in Q3/ Commence Phase I dosing studies in recurrent Glioblastoma Multiforme and brain metastases patients in Q Commence Phase Ib/II investigator-run study at the Medical College of Georgia (and/or another clinical institution in malignant glioma patients in Q

Funding (I) Cytorex is seeking immediate funds of $ 10 Million: To Complete IND preclinical studies, including enabling toxicity studies. To file an IND in its lead indication, Glioblastoma Multiforme. To Complete Phase I and Initiate Phase II in Glioblastoma Multiforme. To continue ongoing prosecution of Cytorex’ IP estate.

Funding (II) Cytorex estimates it requires a total of USD $10 Million to achieve the initial milestones. During the funding process Cytorex will have a preference for investors with an interest in participating in subsequent rounds of funding as the Cytoreg ® development proceeds. Total funding required to obtain FDA approval in the first indication is estimated in Million US$. Total Funding Required: $106 Million

Revenue Potential and Cost Projections Cytorex expects that Cytoreg ® will become a blockbuster drug as a result of its key product advantages. Given the parallel potential of other successful brand therapies, such as Eloxatin ® and expectations that Cytoreg ® ’s performance will exceed Temodar ® due to improved efficacy in Glioblastoma Multiforme and indications beyond gliomas, as well as a favorable side effect profile, peak revenue of Cytoreg ® alone is likely to fall between Temodar ® and Eloxatin ®, representing a peak sales opportunity of USD $1billion to over USD $4 billion annually for the cancer market alone with Cytoreg ®.

Management Team Prof. David Martucci, Chairman, President, Chief Executive Officer and Chief Scientific Officer Mr. William Jimenez, Director, Vice-President, Treasurer and Chief Financial Officer Mr. Carlos M. Garcia, Director, Secretary & Chief Operations Officer Mr. Ramon Alvarez, Business Development Director

Key Advisors Dr. Kris Dhandapani, Scientific Consultant Mr. Michael J. Keller, Intellectual Property Attorney

Cytorex Biosciences, Inc. Carlos M. Garcia, Managing Director & COO 4474 Weston Road No. 108 Weston, FL Direct: Contact Information: